CClinicalTrials.gg
Not yet recruitingNCT06356363OncoPREMsUpdated Apr 10, 2024

Development of a Questionnaire on Patients' Perception of Their Oncology Care Pathway (Onco-PREMs)

An observational study in Cancer, sponsored by Institut Jean-Godinot. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-10.

Sponsored by Institut Jean-Godinot · Observational

Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
500
Ages
18 Years and older
Sex
All
01

Study summary

Healthcare systems are evolving, giving increasing prominence to the patient-centered model, accompanied by objective and perceived outcomes.

PREMs (Patient Reported Experience Measures) are used to assess how patients feel about their experience of care. PREMs enable patients to take an active role in their own care, and enable healthcare establishments to identify areas for improvement that can be incorporated into their quality processes.

In oncology, the collection of patient-perceived quality regarding their care pathway would enable better coordination of their care. While a few initiatives have emerged in the field of PREMs, the development of a reliable questionnaire assessing patient perception of their care pathway in oncology remains a challenge.

Read the detailed description

The aims of the study are to constitute a questionnaire to assess patients' perceptions of their oncology care pathway and to perform its psychometric validation.

02

Conditions studied

  • Cancer

Browse trials for

Keywords

  • Oncology
  • oncology care pathway
  • patients' perception
  • questionnaire
  • psychometric validation
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patient with cancer regardless of location or stage.

Inclusion criteria

  • cancer patient
  • regardless of location or stage
  • Fluent in French
  • aged more than 18 years old
  • Agreeing to take part in the study

Exclusion criteria

Exclusion Criteria:

  • With an estimated life expectancy of less than 3 months
  • In remission, untreated or without follow-up for more than 12 months
  • Protected by law
04

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
500 participants (estimated)
Patient registry
No

Groups and cohorts

  • Cancer patient

    Patient with cancer regardless of location or stage.

    Other: Data collection

Interventions

  • OtherData collection

    data collection

05

What researchers measure

Primary outcomes

  1. Psychometric validation

    Stastistical analysis to confirm the psychometric validation of the IGQ questionnaire

    Time frame: Day 0

06

Study locations

No study locations are listed for this record.

07

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT06356363
Lead sponsor
Institut Jean-Godinot
Collaborators
Université de Reims Champagne-Ardenne
Responsible party
Sponsor
First posted
Apr 10, 2024
Start date
Jun 1, 2024 (estimated)
Primary completion
Nov 1, 2025 (estimated)
Completion
Nov 1, 2025 (estimated)
Last update
Apr 10, 2024

Study contacts

Barbe Coralie, DR
Contact
coralie.barbe1@univ-reims.fr
0326918822 ext. +33
Gestonnairedu CURRS, Dr
Contact
currs@univ-reims.fr
0326918822 ext. +33
DIOURI Loubna
principal investigator · Institut Godinot

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion